Novalis Biotech closes EUR25m biotech acceleration fund
Novalis Biotech, an early-stage venture capital investor in technologies aimed at revolutionising healthcare, has closed its EUR25 million second fund, the Novalis Biotech Acceleration Fund. Both new and returning investors have participated in the fundraising. The second fund investor base includes institutional investors, such as Participatie Maatschappij Vlaanderen (PMV), family
